Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma

Keyphrases

• Bendamustine 100%
• Indolent non-Hodgkin Lymphoma 100%
• Profile Response 100%
• Pharmacokinetic Profile 100%
• Exposure-response 100%
• Nausea 36%
• Dose Profile 18%
• Cmax 18%
• Neutropenia 9%
• Relapsed or Refractory 9%
• High Incidence 9%
• Pharmacokinetics 9%
• Therapeutic Response 9%
• Intravenous Infusion 9%
• Thrombocytopenia 9%
• Multiple Dose 9%
• Rituximab-refractory 9%
• Indolent Lymphoma 9%
• Exposure Status 9%
• Dosing Regimen 9%
• Active Metabolite 9%
• Terminal Phase 9%
• Vomiting 9%
• Safety Measures 9%
• Metabolite Concentrations 9%
• Limited Range 9%
• Antiemetics 9%
• Efficacy Index 9%
• Pharmacokinetic Model 9%
• Responder Status 9%
• Liver Impairment 9%
• HCl Concentration 9%
• β-elimination 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Nonhodgkin Lymphoma 100%
• Pharmacokinetics 100%
• Bendamustine 100%
• Nausea 27%
• Neutropenia 9%
• Rituximab 9%
• Thrombocytopenia 9%
• Elimination 9%
• Active Metabolite 9%
• Bovine Serum Albumin 9%
• Nausea and Vomiting 9%
• Antiemetic Agent 9%
• Mild Hepatic Impairment 9%